Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Keratosis, Actinic 10Condylomata Acuminata 3Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Neoplasms 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Exanthema 1Carcinoma, Non-Small-Cell Lung 1Acne Vulgaris 1

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2B701 protein, Human herpesvirus 6 2valrubicin 1trifluridine tipiracil drug combination 1palbociclib 1enfortumab vedotin 1atezolizumab 1Water 1Sunitinib 1Standard of Care 1Radiation Dose Hypofractionation 1Gemcitabine 1Gels 1Fluorouracil 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urologic Diseases × Gels × Clear all
NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

Phase 2 Completed
14 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡